Logo image of ACIU

AC IMMUNE SA (ACIU) Stock Fundamental Analysis

NASDAQ:ACIU - Nasdaq - CH0329023102 - Common Stock - Currency: USD

2.65  -0.01 (-0.38%)

Fundamental Rating

3

Overall ACIU gets a fundamental rating of 3 out of 10. We evaluated ACIU against 571 industry peers in the Biotechnology industry. ACIU scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ACIU is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ACIU had negative earnings in the past year.
ACIU had a positive operating cash flow in the past year.
ACIU had negative earnings in 4 of the past 5 years.
In the past 5 years ACIU reported 4 times negative operating cash flow.
ACIU Yearly Net Income VS EBIT VS OCF VS FCFACIU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M -60M

1.2 Ratios

The Return On Assets of ACIU (-16.32%) is better than 81.53% of its industry peers.
ACIU has a Return On Equity of -30.62%. This is in the better half of the industry: ACIU outperforms 78.15% of its industry peers.
Industry RankSector Rank
ROA -16.32%
ROE -30.62%
ROIC N/A
ROA(3y)-31.89%
ROA(5y)-21.29%
ROE(3y)-35.71%
ROE(5y)-23.84%
ROIC(3y)N/A
ROIC(5y)N/A
ACIU Yearly ROA, ROE, ROICACIU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACIU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACIU Yearly Profit, Operating, Gross MarginsACIU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

ACIU does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ACIU has been increased compared to 1 year ago.
The number of shares outstanding for ACIU has been increased compared to 5 years ago.
ACIU has a worse debt/assets ratio than last year.
ACIU Yearly Shares OutstandingACIU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
ACIU Yearly Total Debt VS Total AssetsACIU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -0.67, we must say that ACIU is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of -0.67, ACIU is doing good in the industry, outperforming 60.92% of the companies in the same industry.
ACIU has a debt to FCF ratio of 0.07. This is a very positive value and a sign of high solvency as it would only need 0.07 years to pay back of all of its debts.
ACIU has a better Debt to FCF ratio (0.07) than 97.34% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that ACIU is not too dependend on debt financing.
ACIU has a Debt to Equity ratio (0.02) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.07
Altman-Z -0.67
ROIC/WACCN/A
WACC4.95%
ACIU Yearly LT Debt VS Equity VS FCFACIU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 1.86 indicates that ACIU should not have too much problems paying its short term obligations.
ACIU has a worse Current ratio (1.86) than 78.33% of its industry peers.
A Quick Ratio of 1.86 indicates that ACIU should not have too much problems paying its short term obligations.
ACIU has a Quick ratio of 1.86. This is in the lower half of the industry: ACIU underperforms 76.55% of its industry peers.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.86
ACIU Yearly Current Assets VS Current LiabilitesACIU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.00% over the past year.
The Revenue has grown by 279.51% in the past year. This is a very strong growth!
The Revenue has been growing by 15.50% on average over the past years. This is quite good.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%127.78%
Revenue 1Y (TTM)279.51%
Revenue growth 3Y-1.31%
Revenue growth 5Y15.5%
Sales Q2Q%N/A

3.2 Future

ACIU is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.34% yearly.
The Revenue is expected to grow by 54.85% on average over the next years. This is a very strong growth
EPS Next Y14.55%
EPS Next 2Y26.46%
EPS Next 3Y28.41%
EPS Next 5Y18.34%
Revenue Next Year80.09%
Revenue Next 2Y98.24%
Revenue Next 3Y64.77%
Revenue Next 5Y54.85%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ACIU Yearly Revenue VS EstimatesACIU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
ACIU Yearly EPS VS EstimatesACIU Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACIU. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACIU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACIU Price Earnings VS Forward Price EarningsACIU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

ACIU's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ACIU is cheaper than 99.11% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.48
EV/EBITDA N/A
ACIU Per share dataACIU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

ACIU's earnings are expected to grow with 28.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.46%
EPS Next 3Y28.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACIU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AC IMMUNE SA

NASDAQ:ACIU (2/21/2025, 8:00:00 PM)

2.65

-0.01 (-0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/bmo
Earnings (Next)03-12 2025-03-12/amc
Inst Owners28.02%
Inst Owner Change-95.93%
Ins Owners3.06%
Ins Owner ChangeN/A
Market Cap262.19M
Analysts88
Price Target10.2 (284.91%)
Short Float %1.73%
Short Ratio6.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-29.36%
Min EPS beat(2)-183.77%
Max EPS beat(2)125.04%
EPS beat(4)2
Avg EPS beat(4)-8.15%
Min EPS beat(4)-183.77%
Max EPS beat(4)125.04%
EPS beat(8)5
Avg EPS beat(8)-99.82%
EPS beat(12)7
Avg EPS beat(12)-94.17%
EPS beat(16)9
Avg EPS beat(16)-70.02%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.44%
PT rev (3m)-2.44%
EPS NQ rev (1m)-2.67%
EPS NQ rev (3m)-0.27%
EPS NY rev (1m)-0.99%
EPS NY rev (3m)10.04%
Revenue NQ rev (1m)33.44%
Revenue NQ rev (3m)-78.42%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)301.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.76
P/FCF 5.48
P/OCF 5.4
P/B 1.81
P/tB 2.96
EV/EBITDA N/A
EPS(TTM)-0.46
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)0.48
FCFY18.25%
OCF(TTM)0.49
OCFY18.52%
SpS0.46
BVpS1.46
TBVpS0.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.32%
ROE -30.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 105.11%
ROA(3y)-31.89%
ROA(5y)-21.29%
ROE(3y)-35.71%
ROE(5y)-23.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.07
Debt/EBITDA N/A
Cap/Depr 29.8%
Cap/Sales 1.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.86
Altman-Z -0.67
F-Score6
WACC4.95%
ROIC/WACCN/A
Cap/Depr(3y)66.08%
Cap/Depr(5y)79.38%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%127.78%
EPS Next Y14.55%
EPS Next 2Y26.46%
EPS Next 3Y28.41%
EPS Next 5Y18.34%
Revenue 1Y (TTM)279.51%
Revenue growth 3Y-1.31%
Revenue growth 5Y15.5%
Sales Q2Q%N/A
Revenue Next Year80.09%
Revenue Next 2Y98.24%
Revenue Next 3Y64.77%
Revenue Next 5Y54.85%
EBIT growth 1Y45.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.7%
EBIT Next 3Y-8.71%
EBIT Next 5Y-7.72%
FCF growth 1Y156.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y159.09%
OCF growth 3YN/A
OCF growth 5YN/A